Alpha-Synuclein Seed Amplification Assay in CSF, Skin, and Submandibular Gland From Incidental Lewy Body Disease and Parkinson Disease.
A spinal fluid test detects Parkinson's disease pathology years before symptoms appear, opening possibilities for earlier intervention in at-risk individuals.
Using RT-QuIC on autopsy-confirmed ILBD cases, CSF alpha-synuclein seeding assay showed 75.8% sensitivity for incidental (prodromal) Lewy body disease vs only 35% for SMG or skin, with 100% sensitivity in confirmed PD. CSF aSyn SAA can detect pathological aSyn aggregates in Stage I Lewy body disease (olfactory bulb only), potentially enabling presymptomatic PD diagnosis years before motor onset.
What the study was
- Study design
- Autopsy-confirmed cross-sectional biomarker study
- Population
- Autopsy-confirmed incidental Lewy body disease (ILBD), Parkinson disease (PD), and controls (Arizona Study of Aging)
- Sample size
- 74
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Neurology
Why it surfaced
First demonstration of CSF aSyn SAA sensitivity for prodromal Lewy body at Stage I (olfactory bulb only) in autopsy-confirmed ILBD; Neurology journal; directly actionable for presymptomatic Parkinson disease screening programs.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.